The University of Queensland based biotechnology company Protagonist Therapeutics Inc. has secured $14 million in venture financing from new investor Johnson & Johnson Development Corporation and existing investors Lilly Ventures and Starfish Ventures (Melbourne, Australia).
The venture funding will support the discovery and development of Protagonist’s pipeline of oral disulfide rich peptide (DRP) therapeutics that combine the best properties of small molecule drugs and large molecule biologics in a single chemical entity.
Protagonist Therapeutics Inc., was established in 2001 based on research carried out at UQ's Institute for Molecular Bioscience and has now raised more than $23 million towards its goal of developing new drugs for a range of diseases, including inflammatory bowel disease.
It is headquartered at Menlo Park, California and has discovery operations at IMB in the Queensland Bioscience Precinct in Brisbane and at Menlo Park.
The Institute for Molecular Bioscience (IMB) is a research institute of The University of Queensland that aims to improve quality of life by advancing personalised medicine, drug discovery and biotechnology.
Visit Protagonist Therapeutics Inc. Website
